Prosecution Insights
Last updated: November 12, 2026
Application No. 18/837,484

PALM FAT COMPOSITIONS AS SOFT AND SPREADABLE MARGARINES

Non-Final OA §103
Filed
Aug 09, 2024
Priority
Feb 11, 2022 — provisional 63/309,197 +1 more
Examiner
STULII, VERA
Art Unit
1791
Tech Center
1700 — Chemical & Materials Engineering
Assignee
Alianza Team International S A
OA Round
1 (Non-Final)
33%
Grant Probability
At Risk
1-2
OA Rounds
58%
With Interview

Examiner Intelligence

Grants only 33% of cases
33%
Career Allowance Rate
285 granted / 871 resolved
-32.3% vs TC avg
Strong +25% interview lift
Without
With
+24.9%
Interview Lift
resolved cases with interview
Typical timeline
Avg Prosecution
51 currently pending
Career history
927
Total Applications
across all art units

Office Action

§103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Election/Restrictions Applicant's election with traverse of claims 1-12 in the reply filed on 08/03/2026 is acknowledged. The traversal is on the ground(s) that both groups share special technical feature that clearly defines a contribution over the cited prior art. This is not found persuasive for the reasons as state in the rejection of claims 1, 3-4, 6 and 8-12 below. The requirement is still deemed proper and is therefore made FINAL. Claim 13 withdrawn from further consideration pursuant to 37 CFR 1.142(b), as being drawn to a nonelected invention, there being no allowable generic or linking claim. Applicant timely traversed the restriction (election) requirement in the reply filed on 08/03/2026. Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claim(s) 1, 3-4, 6 and 8-12 is/are rejected under 35 U.S.C. 103 as being unpatentable over Boer et al (WO 2010060712 A1). Claim 1 recited the following limitations: A fat composition comprising a fat phase and an aqueous phase, wherein the fat phase is between 10% and 95% w/w of the composition, the aqueous phase is between 5% and 90% w/w of the composition, and wherein the fat phase comprises a fat component of palm oil and/or fractions thereof and a post-crystallization control component, wherein the post crystallization control component comprises a non-ionic surfactant and glycerol partial esters at a ratio of between 1:0.5 to 1:10; wherein the fat component comprises a combination of POP and PPO at a range of 25% to 35% w/w of the total fat component, POO at a range of 20% to 35% w/w of the total fat component, PPP at a range of 3% to 10% w/w of the total fat component, OOO at a range of 5% to 10% w/w of the total fat component, and POS at a range of 2% to 6% w/w of the total fat component, wherein P is palmitic acid, O is oleic acid, and S is stearic acid. In regard to claim 1, Boer et al discloses a “fat containing emulsion comprising palm oil and sorbitan fatty acid ester” ([0001]). Boer et al discloses “[a]n emulsion comprising 20-85 % of a fat phase and an emulsifier, wherein the fat phase comprises HHH, HOH, HOO triacylglycerides wherein H is palmitic or stearic acid and 0 is oleic acid and wherein the ratio of HHH /HOH is from 0.05 to 0.27, the ratio HOO/HHH is from 3 to 8 and wherein HOH the palmitic acid level in the H fractions is at least 60 % and wherein the emulsifier comprises sorbitan ester of fatty acid wherein at least 40% of the sorbitan ester of fatty acid is a sorbitan mono ester of fatty acid” (Claim 1, Abstract, page 4 lines 1-16). In regard to the triglycerides composition and particular ratios as claimed, Boer et al discloses: Some examples of HHH TAGs are the mono-acyl TAGs PPP (tripalmitine) , SSS (tristearine) , but also the mixed TAGs PSP, PPS, SPS, and PSS. The order of the fatty acid in the denotation of the TAGs indicates the symmetry of the TAGs. PSP and SPS are symmetrical TAGs having the same fatty acid on the 1- and 3- position. PPS and PSS are asymmetrical TAGs having different types of fatty acids on the 1- and 3- position. HHH is the total sum of all HHH-type TAGs as described above in the fat. The TAG HOH represents TAGs with on the middle position an oleic acid. The H may be palmitic or stearic, but is not necessarily the same in a single TAG. The group of HOH TAGs comprises POS, POP, and SOS. HOH is the total sum of the HOH- type TAGs present in the fat (page 6 lines 10-24). HOO TAGs are TAGs that have two oleic acid residues, one in the middle position, and one on one of the outer (1- or 3-) position of the glycerol ester. The HOO TAG also contains 1 H residue on one of the outer positions, being either palmitic or stearic acid. Thus two types of HOO TAGs may be present, POO and SOO. HOO is the total sum of HOO TAGs as described above present in the fat. HHH is the total sum of all HHH-type TAGs as described above and HOH is the total sum of the HOH-type TAGs as described above present in the fat. The ratio of HHH /HOH is from 0.05 to 0.27, and the ratio HOO/HHH is from 3 to 8. Preferably the ratio of HHH /HOH is from 0.10 to 0.25, more preferably from 0.15 to 0.20. In a preferred embodiment the ratio HOO/HHH is from 3.25 to 6, and more preferred from 3.25 to 5.75. In another preferred embodiment, in the HOH TAGs the level of palmitic acid of the H fractions is at least 60%; this means that of all H in the total HOH group at least 60% of the H residues is palmitic acid. More preferably at least 70% is palmitic acid, and most preferred at least 80% is palmitic. Suitable emulsions according to the present invention may also comprise HHO TAGs. HHO TAGs consist of TAGs with one oleic acid on one of the terminal positions and one H residue in the middle position and one H residue on one of the terminal positions. H may be palmitic acid or stearic acid. The group of HHO TAGS comprises PPO, SSO, SPO, and PSO. In a preferred embodiment the ratio of HOH/HHO is more than 3, preferably more than 4, more preferably between 3 and 7, and most preferably between 4 and 7. In a preferred embodiment of the present invention the ratio of HOO/ (HOH+HHH) is from 0.65 to 0.8, more preferably from 0.65 to 0.75 and most preferably from 0.65 to 0.7. The ratio HOO/ (HOH+HHH) is the ratio of all HOO TAGs present in the fat to the combined sum of all HOH TAGs and all HHH TAGs present in the fat (page 7 lines 5-32). In regard to the fat phase content, Boer et al discloses “[e]mulsions according to the invention comprise 20-85 wt% fat, preferably 40-80 wt% fat, and more preferably 50 to 65 wt% of fat” (page 8 lines 24-26). Boer et al discloses “[p]referably 0.05 to 2 wt% of sorbitan ester of fatty acid is present in the emulsion according to the invention” (page 8 lines 28-29). Boer et al discloses “[i]n preferred embodiment the emulsion of the present invention comprises an aqueous phase” (page 11 lines 7-8). Boer et al further discloses the following exemplary embodiments of the fat composition: Product 1, according to the invention: Composition of product: Fatphase: 60% fatblend, 0.25% Span 60 0.10% Monoglycerides (Dimodan HP) 0.10% Lecithin (Sunlec M) Water phase 39.15% water 0.4% salt Span 60 characteristics: Degree of esterification between mono-, di-, and tri- fatty acid ester of sorbitol 61.5 % mono esters 34 % di esters 4.5 % tri esters Composition of fatty acid moieties 54 % palmitic acid 44 % stearic acid 2 % oleic acid Fatblend: is mix of 24% palm oil 12% of a dry fractionated palm olein (iodine value 55), and 64% of sunflower oil. The oil is characterised by the following: Triglyceride profile HHH 1.9 % (w/w) , HOH 11.4% (w/w), HHO 2.1 % (w/w) , HLH 5 % (w/w) , HOO 9.2 % (w/w) Ratios of triglycerides HHH/HOH 0.167 OR HOH/HHH 6 HHH/HOO 0.207 OR HOO/HHH 4.84 HOO/ (HHH+HOH) 0.69 H being palmitic acid or stearic acid O is oleic acid and L is linoleic acid 90% of H in HOH is palmitic acid Solid fat content at 5°C is 16.3 %, SFC at 20<0>C is 3.8%. Level of saturated fatty acids is 25.8 % (w/w) Symmetry ratio of the H20 triglycerides HOH/HHO is 5.4 (pages 16-17) Boer et al discloses Product 2 (Example 2) and product 3 (Example 3) (pages 24-25 and 30-31). Further in regard to the concentrations recitations, it is noted that: Generally, differences in concentration or temperature will not support the patentability of subject matter encompassed by the prior art unless there is evidence indicating such concentration or temperature is critical. "[W]here the general conditions of a claim are disclosed in the prior art, it is not inventive to discover the optimum or workable ranges by routine experimentation." In re Aller, 220 F.2d 454, 456, 105 USPQ 233, 235 (CCPA 1955) (MPEP 2144.05, II A). Further, regarding the concentrations ranges as examined above, it is noted that in the case where the claimed ranges “overlap or lie inside ranges disclosed by the prior art” a prima facie case of obviousness exists. In re Wertheim, 541 F.2d 257, 191 USPQ 90 (CCPA 1976); In re Woodruff, 919 F.2d 1575, 16 USPQ2d 1934 (Fed. Cir. 1990). Similarly, a prima facie case of obviousness exists where the claimed ranges or amounts do not overlap with the prior art but are merely close. Titanium Metals Corp. of America v. Banner, 778 F.2d 775, 783, 227 USPQ 773, 779 (Fed. Cir. 1985). In regard to claim 3, Boer et al discloses: The emulsifier comprises sorbitan ester of fatty acid. Sorbitan ester of fatty acid, maybe mono-, di, or tri- ester (page 8 lines 1-4). In regard to claim 6, Boer et al discloses: Suitably the fatty acid in the sorbitan ester of fatty acid is selected from the group comprising, lauric acid, myristic acid, palmitic acid, stearic acid, or oleic acid. The sorbitan fatty acid ester in the present invention may be a mix of sorbitan esters with different fatty acids. In a preferred embodiment the fatty acid in the sorbitan ester of fatty acid is a ratio of stearic to palmitic fatty acid between 3 to 1 and 1 to 3, more preferred between 2 to 1 and 1 to 2, and most preferred between 6 to 4 and 4 to 6. Another preferred embodiment of the invention is that the degree of esterification of the sorbitan esters is such that in the sum of mono-, di-, and tri- esters the mono-esters account for at least 40 %, more preferred at least 50% and most preferred for at least 60%. In a preferred embodiment the combined amount of stearic acid and palmitic acid in the sorbitan ester of fatty acid is at least 40% of the total amount of fatty acids in the sorbitan ester (page 8 lines 6-22). In regard to claims 4 and 8, Boer et al discloses: Boer et al discloses “[a]n emulsion comprising 20-85 % of a fat phase and an emulsifier, wherein the fat phase comprises HHH, HOH, HOO triacylglycerides wherein H is palmitic or stearic acid and 0 is oleic acid and wherein the ratio of HHH /HOH is from 0.05 to 0.27, the ratio HOO/HHH is from 3 to 8 and wherein HOH the palmitic acid level in the H fractions is at least 60 % and wherein the emulsifier comprises sorbitan ester of fatty acid wherein at least 40% of the sorbitan ester of fatty acid is a sorbitan mono ester of fatty acid” (Claim 1, Abstract, page 4 lines 1-16). In regard to claims 9 and 11, Boer et al discloses ‘[t]he emulsion according to the invention optionally contain other ingredients such as preservatives, vitamins, taste and flavour components, colorants such as beta-carotene, antioxidants” (page 11 lines 31-32, page 12 lines 1-2). In regard to claim 11, Boer et al discloses that composition further comprises milk (page 11 lines 20-24). In regard to claim 10, Boer et al discloses lecithin and sorbitan esters (page 10 lines 10-14; page 8 lines 1-4). In regard to claim 12, Boer et al discloses margarine or spread (page 1). Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to VERA STULII whose telephone number is (571)272-3221. The examiner can normally be reached Monday-Friday 5:30AM-3:30PM. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Nikki Dees can be reached at 571-270-3435. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /VERA STULII/Primary Examiner, Art Unit 1791
Read full office action

Prosecution Timeline

Aug 09, 2024
Application Filed
Oct 19, 2026
Non-Final Rejection mailed — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12790572
METHOD FOR IMPROVING AFTERTASTE OF ALCOHOLIC BEVERAGES USING ALLULOSE
2y 9m to grant Granted Nov 10, 2026
Patent 12781163
NOVEL EXTRACT, METHOD FOR PRODUCING SAME, AND USE THEREOF
3y 4m to grant Granted Nov 03, 2026
Patent 12778170
COATED SWEETENER PARTICLES
2y 1m to grant Granted Nov 03, 2026
Patent 12765569
FOOD PRODUCTS AND SYSTEMS AND METHODS OF MAKING SAME
1y 5m to grant Granted Oct 20, 2026
Patent 12757910
Dry-Powdered Cheese Compositions with Naturally-Derived Color Blends, Method of Making and Cheese Product
2y 6m to grant Granted Oct 13, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
33%
Grant Probability
58%
With Interview (+24.9%)
Low
PTA Risk
Based on 871 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month